Biogen to Pay Elan $3.25 Billion for Full Rights to Tysabri

Biogen to Pay Elan $3.25 Billion for Full Rights to Tysabri

Biogen Inc. via Bloomberg

Tysabri has shown higher efficacy in staving off the neurological attacks that characterize relapsing MS.